Asarina Pharma Q3’20: Operational Progress

Research Note

2020-11-25

10:39

Redeye notes that Asarina Pharma remains on track to report and initiate phase 2a studies in Q2'21. The finances came in largely as expected.

AH

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.